Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
CH0013841017
Wed, 08.05.2024
Lonza Group AG
Lonza Group AG
/ Key word(s): AGMEGM
Lonza Announces Results of the 2024 Annual General Meeting – All Motions Proposed by Board of Directors Approved 08.05.2024 / 15:00 CET/CEST
Jean-Marc Huët was elected as Chairman of the Board of Directors
Shareholders re-elected all members of the Board of Directors standing for re-elect [ … ]
Wed, 17.04.2024
Lonza Group AG
Lonza Group AG
/ Key word(s): Bond/Financing
Lonza Prices EUR 1 Billion Straight Bond with a 3.875% Coupon 17.04.2024 / 19:00 CET/CEST
Basel, Switzerland, 17 April 2024 – Lonza Finance International NV, a wholly owned company of Lonza Group Ltd, Basel (“Lonza”), announced today the pricing of a EUR 1 billion straight bond. The [ … ]
Mon, 06.11.2023
Lonza Group AG
Lonza Group AG
/ Key word(s): Bond/Financing
Lonza Prices CHF 400 Million Dual-Tranche Straight Bonds
06.11.2023 / 18:30 CET/CEST
Basel, Switzerland, 06 November 2023 – Lonza Swiss Finance Ltd, a wholly owned company of Lonza Group Ltd, Basel (“Lonza”), announced today the pricing of a CHF 400 million dual-tranche strai [ … ]
Fri, 13.10.2023
Lonza Group AG
Lonza Group AG
/ Key word(s): Expansion
Lonza Announces New Filling Line for Commercial Supply of Antibody-Drug Conjugates for a Dedicated Customer
13.10.2023 / 08:00 CET/CEST
The new cGMP filling line at Lonza’s Stein (CH) site will enable handling and filling of bioconjugates for commercial supply
Expansion [ … ]
Thu, 01.06.2023
Lonza Group AG
Lonza Group AG
/ Key word(s): Acquisition/Mergers & Acquisitions
Lonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering
01.06.2023 / 07:00 CET/CEST
Lonza to acquire Synaffix B.V., an innovative biotech company focused on antibody-drug conjugates (ADCs)
Acquisition will further strengthen Lonza’s biocon [ … ]
Thu, 01.06.2023
Lonza Group AG
Lonza Group AG
/ Key word(s): Acquisition/Mergers & Acquisitions
Lonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering
01.06.2023 / 07:00 CET/CEST
Lonza to acquire Synaffix B.V., an innovative biotech company focused on antibody-drug conjugates (ADCs)
Acquisition will further strengthen Lonza’s biocon [ … ]
Fri, 05.05.2023
Lonza Group AG
Lonza Group AG
/ Key word(s): AGMEGM
Lonza Announces Results of the 2023 Annual General Meeting – All Motions Proposed by Board of Directors Accepted
05.05.2023 / 15:00 CET/CEST
Shareholders re-elected all existing members of the Board of Directors
Albert M. Baehny was re-elected as Chairman of the Board of Directors
A divide [ … ]
Fri, 05.05.2023
Lonza Group AG
Lonza Group AG
/ Key word(s): AGMEGM
Lonza Announces Results of the 2023 Annual General Meeting – All Motions Proposed by Board of Directors Accepted
05.05.2023 / 15:00 CET/CEST
Shareholders re-elected all existing members of the Board of Directors
Albert M. Baehny was re-elected as Chairman of the Board of Directors
A divide [ … ]
Thu, 20.04.2023
Lonza Group AG
Lonza Group AG
/ Key word(s): Bond/Financing
Lonza Increases Straight Bond by CHF 150 Million
20.04.2023 / 18:30 CET/CEST
Basel, Switzerland, 20 April 2023 – Lonza Swiss Finance Ltd, a wholly owned company of Lonza Group Ltd, Basel (“Lonza”), announced today the increase of the Straight Bond issued on 8 February 2023 by CHF 150 m [ … ]
Thu, 20.04.2023
Lonza Group AG
Lonza Group AG
/ Key word(s): Bond/Financing
Lonza Increases Straight Bond by CHF 150 Million
20.04.2023 / 18:30 CET/CEST
Basel, Switzerland, 20 April 2023 – Lonza Swiss Finance Ltd, a wholly owned company of Lonza Group Ltd, Basel (“Lonza”), announced today the increase of the Straight Bond issued on 8 February 2023 by CHF 150 m [ … ]